Loading clinical trials...
Loading clinical trials...
This is a randomized, double-blind, placebo-controlled crossover study of single-dose intranasal oxytocin (24 IU) in 18-55 year-old men with attention deficit/hyperactivity disorder (ADHD). Following ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Massachusetts General Hospital
NCT06133231 · Attention Deficit/Hyperactivity Disorder, Emotional Dysfunction, and more
NCT05721235 · Attention Deficit/Hyperactivity Disorder
NCT07098585 · Attention Deficit/Hyperactivity Disorder (ADHD)
NCT04189575 · Attention Deficit/Hyperactivity Disorder
NCT04189562 · Attention Deficit/Hyperactivity Disorder
Massachusetts General Hospital
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions